₹3,818.30
−0.76%NSE close, 16 Nov 2026
−24.76%
Pfizer is a small cap company in the Healthcare sector, listed on NSE under the symbol PFIZER. At ₹3,818.30 a share, the market values the whole company at ₹17,468 crore.
In FY26, it reported sales of ₹2,520 crore and a net profit of ₹722 crore, an operating margin of 35.9%. Over the last three years, sales grew 1.3% a year and net profit grew 5.0% a year.
The market values the company at 20.3 times its profit over the last twelve months and 3.98 times its book value; its return on equity is 19.6% and it has almost no borrowings.
Promoters hold 63.92% of the shares. Foreign institutions hold 1.63%, and domestic institutions, mutual funds among them, 17.52%.
Over the past year the share price has fallen 24.7%, and it is 28.5% below its 52-week high.
Companies of a similar size in the same sector include Onesource Specialty Pharma, Eris Lifesciences, Shilpa Medicare and Caplin Point Laboratories.
₹ crore. Standalone figures: the company files no consolidated results.
The same sector (Healthcare), nearest in size.
| Company | Price | Market cap | P/E | ROE | Sales growth | 1Y |
|---|---|---|---|---|---|---|
| Pfizer | ₹3,818.30 | ₹17,468 cr | 20.3 | 19.6% | +13.20% | −24.65% |
| Onesource Specialty Pharma | ₹1,612.70 | ₹18,493 cr | n/a | 0.0% | +37.40% | −10.09% |
| Eris Lifesciences | ₹1,329.70 | ₹18,427 cr | 26.0 | 17.1% | +12.60% | −16.13% |
| Shilpa Medicare | ₹938.35 | ₹18,352 cr | 55.2 | 12.1% | +43.00% | +154.50% |
| Caplin Point Laboratories | ₹2,346.80 | ₹17,838 cr | 25.9 |
The financial results for the period ended September 30, 2026.
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Company has, on September 28, 2026, received an Order dated September 25, 2026, issued by the Deputy / Additional Commissioner of Income tax…
Written from the company's filings with NSE and the exchanges' daily prices. For information only, not a recommendation to buy, sell or hold any security.
| Dec 2025 |
|---|
| Mar 2026 |
|---|
| Jun 2026 |
|---|
| Sep 2026 |
|---|
| Sales | 540 | 547 | 563 | 589 | 538 | 592 | 603 | 642 | 645 | 629 | 653 | 727 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 387 | 357 | 385 | 399 | 392 | 364 | 393 | 412 | 417 | 393 | 406 | 466 |
| Operating profit | 153 | 189 | 177 | 189 | 146 | 228 | 210 | 230 | 228 | 236 | 248 | 261 |
| Operating margin | 28.3% | 34.7% | 31.5% | 32.2% | 27.1% | 38.4% | 34.8% | 35.8% | 35.4% | 37.5% | 37.9% | 35.9% |
| Other income | 35.9 | 75.1 | 41.8 | 43.1 | 42.8 | 44.6 | 67.2 | 41.9 | 38.2 | 40.7 | 44.8 | 47.3 |
| Interest | 2.9 | 7.0 | 2.1 | 2.1 | 1.5 | 2.7 | 3.3 | 2.1 | 2.0 | 2.1 | 1.5 | 3.4 |
| Depreciation | 17.6 | 13.8 | 14.6 | 15.0 | 14.8 | 16.4 | 14.4 | 14.3 | 14.3 | 14.8 | 14.3 | 14.4 |
| Profit before tax | 176 | 244 | 203 | 215 | 172 | 426 | 260 | 255 | 192 | 269 | 277 | 423 |
| Tax | 46.0 | 65.0 | 51.9 | 56.9 | 44.8 | 94.9 | 67.8 | 66.4 | 50.1 | 69.0 | 72.2 | 110 |
| Net profit | 130 | 179 | 151 | 158 | 128 | 331 | 192 | 189 | 142 | 200 | 204 | 313 |
| EPS (₹) | 27.12 | 22.33 | 32.94 | 34.61 | 27.89 | 72.34 | 41.91 | 41.32 | 31.01 | 43.68 | 44.69 | 68.47 |
₹ crore, financial years to March.
| Line | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Sales | 2,082 | 2,152 | 2,239 | 2,611 | 2,425 | 2,193 | 2,281 | 2,520 |
| Expenses | 1,516 | 1,579 | 1,526 | 1,775 | 1,616 | 1,558 | 1,541 | 1,616 |
| Operating profit | 565 | 573 | 712 | 836 | 809 | 635 | 740 | 904 |
| Operating margin | 27.2% | 26.6% | 31.8% | 32.0% | 33.4% | 29.0% | 32.4% | 35.9% |
| Other income | 167 | 184 | 81.1 | 62.7 | 101 | 181 | 172 | 188 |
| Interest | 1.3 | 10.9 | 15.1 | 10.5 | 13.4 | 15.4 | 8.4 | 9.5 |
| Depreciation | 71.4 | 103 | 109 | 115 | 106 | 62.3 | 60.8 | 57.7 |
| Profit before tax | 660 | 642 | 669 | 773 | 824 | 746 | 1,016 | 976 |
| Tax | 231 | 133 | 171 | 160 | 200 | 195 | 248 | 253 |
| Net profit | 429 | 509 | 498 | 613 | 624 | 551 | 768 | 722 |
| EPS (₹) | 93.78 | 111.28 | 108.77 | 133.89 | 136.37 | 102.45 | 167.79 | 157.92 |
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY22 | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|---|
| From operations | 667 | 660 | 968 | 359 |
| From investing | −575 | −71.3 | −562 | −2.8 |
| From financing | −181 | −205 | −798 | −366 |
| Spent on fixed assets | −15.3 | −28.2 | −25.2 | −24.4 |
| Free cash flow | 652 | 632 | 942 | 335 |
Margins, returns, debt, tax and cash.
| Line | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Net margin | 20.6% | 23.7% | 22.2% | 23.5% | 25.7% | 25.1% | 33.6% | 28.7% |
| Operating margin | 27.2% | 26.6% | 31.8% | 32.0% | 33.4% | 29.0% | 32.4% | 35.9% |
| Return on equity | – | – | – | – | 19.5% | 15.3% | 18.2% | 17.2% |
| Return on capital employed | – | – | – | – | 26.1% | 21.2% | 24.3% | 23.4% |
| Return on assets | – | – | – | – | 15.6% | 13.0% | 15.6% | 14.7% |
| Debt to equity | – | – | – | – | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest coverage | 512.60 | 60.20 | 45.30 | 74.70 | 62.50 | 49.40 | 121.80 | 103.90 |
| Debt to assets | – | – | – | – | 0.00 | 0.00 | 0.00 | 0.00 |
| Current ratio | – | – | – | – | 3.79 | 5.01 | 6.17 | 6.06 |
| Quick ratio | – | – | – | – | 3.16 | 4.22 | 5.33 | 5.31 |
| Cash ratio | – | – | – | – | 0.06 | 0.20 | 0.87 | 0.16 |
| Asset turnover | – | – | – | – | 0.61 | 0.52 | 0.46 | 0.51 |
| Fixed asset turnover | – | – | – | – | 13.66 | 14.53 | 13.28 | 18.51 |
| Inventory turnover | – | – | – | – | – | 1.80 | 1.70 | 1.90 |
| Receivables turnover | – | – | – | – | 16.00 | 11.70 | 11.80 | 13.90 |
| Gross margin | – | – | – | – | – | 63.9% | 64.5% | 64.9% |
| Cash from operations to profit | – | – | – | 109.0% | – | – | 86.0% | 134.0% |
| Effective tax rate | 35.0% | 20.8% | 25.6% | 20.7% | 24.3% | 26.1% | 24.5% | 26.0% |
| 17.7% |
| +17.90% |
| +17.08% |
| Syngene International | ₹441.20 | ₹17,810 cr | 95.7 | 3.8% | −8.60% | −28.91% |
|---|
| Cohance Lifesciences | ₹457.60 | ₹17,508 cr | 369.6 | 1.2% | −14.20% | −36.78% |
|---|
| Poly Medicure | ₹1,684.30 | ₹17,072 cr | 53.6 | 9.8% | +30.80% | −11.21% |
|---|
| Natco Pharma | ₹828.65 | ₹16,255 cr | 19.6 | 8.5% | −29.00% | +3.52% |
|---|
Please find enclosed outcome of the Board Meeting held today i.e., September 7, 2026.
A copy Srutinizers report of Annual General Meeting held on July 28, 2026. Further, the company has informed the Exchange regarding voting results.
Proceedings of Annual General Meeting held on July 28, 2026
The financial results for the period ended Jun 30, 2026.
Change in Director(s) of the company.
The Exchange has sought clarification from Pfizer Limited with respect to recent news item captioned Pfizer suspends Premarin vaginal cream in India, raising concerns over menopause care.. The response from the Company is attached.
The Exchange has sought clarification from Pfizer Limited with respect to recent news item captioned Pfizer suspends Premarin vaginal cream in India, raising concerns over menopause care.. The response from the Company is awaited.
Letter to shareholders providing the weblink to access the Annual Report for Financial Year 2025 26.
Notice of undefined to be held on July 28, 2026
A copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.